Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Q2 2026 Earnings Presentation
18 slides from Prestige Consumer Healthcare's earnings presentation, Nov 6, 2025
Slide 1: Second Quarter FY 26 Results
Second Quarter FY 26 Results November 6, 2025
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, diluted adjusted E
Slide 3: Agenda for Today's Discussion
Agenda for Today’s Discussion I. Performance Update II. Financial Overview III. FY 26 Outlook SECOND QUARTER FY 26 RESULTS 3
Slide 4: I. Performance Update
I. Performance Update SECOND QUARTER FY 26 RESULTS
Slide 5: Q2 FY 26 Performance Update
Q2 FY 26 Performance Update ◼ Quarterly Revenue of $274.1 million Q2 FY 26 Sales ◼ Revenue better than forecast, due to Clear Eyes supply timing and retail order Drivers timing ◼ eCommerce sales continue to benefit from long-term investments ◼ Gross Margin of 55.3%, as expected and approximately fla
Slide 6: Brand-Building through Iconic Campaigns
Brand-Building through Iconic Campaigns Dental Guards – A Strategic Focus Area Agile Marketing Playbook Accelerating Growth Private label 50%+ Market Share* #2 brand Social Media National Sponsored Brand PR & Podcasts Sponsorship Others & Influencers TV Video & Ads Earned Media Estimated Guards Mark
Slide 7: II. Financial Overview
II. Financial Overview SECOND QUARTER FY 26 RESULTS
Slide 8: Q2 FY 26 Performance Highlights
Q2 FY 26 Performance Highlights (3.4%) Revenue of $274.1 million, down 3.3% vs. prior year excluding foreign currency(1) $283.8 $274.1 (5.5%) EBITDA(2) of $86.8 million vs. $91.9 million prior $86.8 $91.9 (1.8%) year $1.07 $1.09 Adjusted Diluted EPS(2) of $1.07 down 1.8% vs. Revenue EBITDA (2) Adj.
Slide 9: FY 26 Second Quarter and 1H Consolidated Financial Summary
FY 26 Second Quarter and 1H Consolidated Financial Summary 3 Months Ended 6 Months Ended 1H Comments Q2 FY 26 Q2 FY 25 % Chg 1H FY 26 1H FY 25 % Chg ◼ Organic Revenue(1) down 4.8% vs. prior year Total Revenue $ 274.1 $ 283.8 (3.4%) $ 523.6 $ 550.9 (5.0%) – Sales declines due to Clear Eyes supply Gro
Slide 10: Industry Leading Free Cash Flow Trends
Industry Leading Free Cash Flow Trends Free Cash Flow(2) Comments Q2 FY 26 Q2 FY 25 1H FY 26 1H FY 25 ◼ Total 1H Free Cash Flow(2) of $133.6 million up 10% vs. prior year – Full-year free cash flow outlook(5) of $245 million $133.6 or more unchanged $121.4 – Strong business attributes continue to dr
Slide 11: III. FY 26 Outlook
III. FY 26 Outlook SECOND QUARTER FY 26 RESULTS
Slide 12: FY 26 Outlook
FY 26 Outlook ◼ Benefitting from well-diversified portfolio and brand-building playbook ◼ Revenues of $1,100 to $1,115 million Top Line Trends — Expected organic revenue down approximately (1.5%) to (3.0%) — Continue to anticipate higher Clear Eyes shipments in 2H via strategic actions ◼ Adjusted Di
Slide 13: Q&A
Q&A SECOND QUARTER FY 26 RESULTS
Slide 14: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measures in the attached Reconciliation Schedules and / or our earnings release dated November 6, 2025 in the “About Non-GAAP Financial Measures” section. (2) EBITDA & EBITDA Mar
Slide 15: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Change Three Months Ended September 30, Six Months Ended September 30, 2025 2024 2025 2024 (In Thousands) GAAP Total Revenues $ 274,114 $ 283,785 $ 523,644 $ 550,927 Revenue Change (3.4%) (5.0%) Adjustments: Impact of foreign currency exchange rates - (370) -
Slide 16: Reconciliation Schedules (continued)
Reconciliation Schedules (continued) Adjusted Diluted EPS Three Months Ended September 30, Six Months Ended September 30, 2025 2024 2025 2024 Net Adjusted Net Adjusted Net Adjusted Net Adjusted Income EPS Income EPS Income EPS Income EPS (In Thousands, except per share data) GAAP Net Income and Dilu
Slide 17: Reconciliation Schedules (continued)
Reconciliation Schedules (continued) Projected Adjusted Diluted EPS Low High Projected FY'26 GAAP Diluted EPS $ 4.33 $ 4.37 Adjustments: Normalized tax rate adjustment (a) 0.21 0.21 Projected FY'26 Non-GAAP Adjusted Diluted EPS $ 4.54 $ 4.58 (a) Income tax adjustment to adjust for discrete income ta
Slide 18: PCH Confidential and Proprietary Information
PCH CONFIDENTIAL AND PROPRIETARY INFORMATION
Prestige Consumer Healthcare — Q2 2026 Earnings Presentation on 6ix